Foreign Investment Inflows: US Pharma Firm Eli Lilly to Invest $1 Billion In Telangana; Details Here | Business News

It will increase the availability of Lilly’s key drugs, including those for obesity, diabetes, Alzheimer’s, cancer and autoimmune conditions.

US-based pharmaceutical giant Eli Lilly will invest $1 billion (over Rs 8,800 crore) in Telangana to expand its manufacturing base and strengthen its global medicine supply chain, the state government announced on Monday.

The investment was confirmed after a delegation from Eli Lilly met Chief Minister A Revanth Reddy and Industries Minister D Sridhar Babu at the Integrated Command Control Centre in Hyderabad.

According to an official release, “Telangana secured a massive investment of $1 billion by US pharma major Eli Lilly, which will expand its manufacturing and global medicine supply capacity in Hyderabad.”

The expansion plan includes a new manufacturing and quality presence, which is expected to create significant employment opportunities for the state’s youth. The move will increase the availability of Lilly’s key drugs, including those for obesity, diabetes, Alzheimer’s, cancer and autoimmune conditions.

“We are making significant investments to increase manufacturing and medicine supply capacity around the world,” Patrik Jonsson, president of Lilly International, said, adding, India is a hub for capability building within its global network.

Chief Minister Revanth Reddy said the move reinforces Hyderabad’s position as a global hub for healthcare innovation, while Minister Sridhar Babu added that the investment underlines Telangana’s rapid industrial growth and growing influence in advanced healthcare manufacturing.

Eli Lilly already operates a commercial site in Gurugram and specialised centres in Bengaluru and Hyderabad supporting its global operations. The new facilities will further enhance its local technical capabilities and broaden its manufacturing footprint in India.

Last month, Lilly announced a $5 billion investment in a new facility in Virginia, part of a $27 billion expansion plan to build four new US plants over the next five years.

Meanwhile, the India launch of Mounjaro, alongside Danish drugmaker Novo Nordisk’s Wegovy, has increased patient awareness of obesity treatments in a country projected to have the world’s second-largest obese population by 2050.

Sales of both drugs doubled within months of their launch.

Lilly is also preparing for increased competition from India’s generic drugmakers, who are racing to launch cheaper versions of Wegovy once its main chemical ingredient, semaglutide, goes off patent next year.

(With inputs from agencies)